> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 Zydelig Lymphoma Indications Withdrawn
- URL: https://www.fdaweb.com/2-zydelig-lymphoma-indications-withdrawn/
- Published: 2022-05-25T12:00:00.000Z
- Updated: 2026-09-14T17:46:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151897

*Federal Register* notice: FDA is announcing that it is withdrawing certain indications that received accelerated approval in a Gilead NDA for Zydelig (idelalisib) because the firm failed to demonstrate a clinical benefit in required postmarketing trials. The indications being withdrawn are for relapsed follicular lymphoma and relapsed small lymphocytic lymphoma. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-11277.pdf?ref=fdaweb.com).